TY - JOUR AU - Ang, K. K. AU - Berkey, B. A. AU - Tu, X. AU - Zhang, H. Z. AU - Katz, R. AU - Hammond, E. H. AU - Fu, K. K. AU - Milas, L. PY - 2002 DA - 2002// TI - Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma JO - Cancer Res VL - 62 ID - Ang2002 ER - TY - JOUR AU - Bonner, J. A. AU - Harari, P. M. AU - Giralt, J. AU - Azarnia, N. AU - Shin, D. M. AU - Cohen, R. B. AU - Jones, C. U. AU - Sur, R. AU - Raben, D. AU - Jassem, J. PY - 2006 DA - 2006// TI - Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa053422 DO - 10.1056/NEJMoa053422 ID - Bonner2006 ER - TY - JOUR AU - Bonner, J. A. AU - Harari, P. M. AU - Giralt, J. AU - Cohen, R. B. AU - Jones, C. U. AU - Sur, R. K. AU - Raben, D. AU - Baselga, J. AU - Spencer, S. A. AU - Zhu, J. PY - 2010 DA - 2010// TI - Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70311-0 DO - 10.1016/S1470-2045(09)70311-0 ID - Bonner2010 ER - TY - JOUR AU - Vermorken, J. B. AU - Mesia, R. AU - Rivera, F. AU - Remenar, E. AU - Kawecki, A. AU - Rottey, S. AU - Erfan, J. AU - Zabolotnyy, D. AU - Kienzer, H. R. AU - Cupissol, D. PY - 2008 DA - 2008// TI - Platinum-based chemotherapy plus cetuximab in head and neck cancer JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0802656 DO - 10.1056/NEJMoa0802656 ID - Vermorken2008 ER - TY - JOUR AU - Vermorken, J. B. AU - Trigo, J. AU - Hitt, R. AU - Koralewski, P. AU - Diaz-Rubio, E. AU - Rolland, F. AU - Knecht, R. AU - Amellal, N. AU - Schueler, A. AU - Baselga, J. PY - 2007 DA - 2007// TI - Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.06.7447 DO - 10.1200/JCO.2006.06.7447 ID - Vermorken2007 ER - TY - STD TI - Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer (clinicaltrials.gov identifier: NCT01302834). [http://clinicaltrials.gov/ct2/show/NCT01302834] UR - http://clinicaltrials.gov/ct2/show/NCT01302834 ID - ref6 ER - TY - JOUR AU - Park, D. AU - Yun, J. AU - Park, J. AU - Oh, S. AU - Kim, H. AU - Cho, Y. AU - Sohn, C. AU - Jeon, W. AU - Kim, B. AU - Yoo, C. PY - 2006 DA - 2006// TI - HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer JO - Digestive Diseases and Sciences VL - 51 UR - https://doi.org/10.1007/s10620-005-9057-1 DO - 10.1007/s10620-005-9057-1 ID - Park2006 ER - TY - JOUR AU - Fujimoto-Ouchi, K. AU - Sekiguchi, F. AU - Yasuno, H. AU - Moriya, Y. AU - Mori, K. AU - Tanaka, Y. PY - 2007 DA - 2007// TI - Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models JO - Cancer Chemotherapy and Pharmacology VL - 59 UR - https://doi.org/10.1007/s00280-006-0337-z DO - 10.1007/s00280-006-0337-z ID - Fujimoto-Ouchi2007 ER - TY - JOUR AU - Bang, Y. J. AU - Van Cutsem, E. AU - Feyereislova, A. AU - Chung, H. C. AU - Shen, L. AU - Sawaki, A. AU - Lordick, F. AU - Ohtsu, A. AU - Omuro, Y. AU - Satoh, T. PY - 2010 DA - 2010// TI - Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial JO - Lancet VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)61121-X DO - 10.1016/S0140-6736(10)61121-X ID - Bang2010 ER - TY - JOUR AU - Wang, J. AU - Saukel, G. W. AU - Garberoglio, C. A. AU - Srikureja, W. AU - Hsueh, C. T. PY - 2010 DA - 2010// TI - Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report JO - J Hematol Oncol VL - 3 UR - https://doi.org/10.1186/1756-8722-3-31 DO - 10.1186/1756-8722-3-31 ID - Wang2010 ER - TY - STD TI - A phase III trial evaluating the addition of trastuzumab to trimodality treatment of HER2-overexpressing esophageal adenocarcinoma (clinicaltrials.gov identifier: NCT01196390 ). [http://clinicaltrials.gov/ct2/show/NCT01196390] UR - http://clinicaltrials.gov/ct2/show/NCT01196390 ID - ref11 ER - TY - STD TI - HerFLOT: Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin in combination With trastuzumab in patients With HER2-positive, locally advanced, resectable adenocarcinoma of the gastroesophageal junction or stomach (clinicaltrials.gov identifier: NCT01472029). [http://clinicaltrials.gov/ct2/show/NCT01472029] UR - http://clinicaltrials.gov/ct2/show/NCT01472029 ID - ref12 ER - TY - STD TI - An open-label, multi-center study to evaluate the disease free survival rate of a perioperative combination of capecitabine (xeloda), trastuzumab and oxaliplatin (XELOX- Trastuzumab) in patients with resectable gastric or gasro-esophageal junction adenocarcinoma (clinicaltrials.gov identifier: NCT01130337). [http://clinicaltrials.gov/ct2/show/NCT01130337] UR - http://clinicaltrials.gov/ct2/show/NCT01130337 ID - ref13 ER - TY - JOUR AU - Baselga, J. AU - Cortes, J. AU - Kim, S. B. AU - Im, S. A. AU - Hegg, R. AU - Im, Y. H. AU - Roman, L. AU - Pedrini, J. L. AU - Pienkowski, T. AU - Knott, A. PY - 2011 DA - 2011// TI - Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1113216 DO - 10.1056/NEJMoa1113216 ID - Baselga2011 ER - TY - STD TI - An open-label, randomized, multicenter phase IIa study evaluating pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive advanced gastric cancer (clinicaltrials.gov identifier: NCT01461057). [http://clinicaltrials.gov/ct2/show/NCT01461057] UR - http://clinicaltrials.gov/ct2/show/NCT01461057 ID - ref15 ER -